Ten people worldwide have been confirmed cured of HIV since 2009, marking a historic shift in the fight against a virus once considered a death sentence. These cases, all arising incidentally during cancer treatment, demonstrate that HIV eradication is biologically possible, though the approach remains impractical for widespread use. The first and most famous case is Timothy Ray Brown, known as the “Berlin patient,” who underwent a stem cell transplant in 2007 to treat acute myeloid leukemia. His donor carried a rare genetic mutation, CCR5-delta32, which prevents HIV from entering immune cells. After stopping antiretroviral therapy, Brown showed no detectable virus and remained free of HIV until his death in 2020 from a leukemia relapse.
The most recent confirmed case, reported in April 2026, involves a 62-year-old man from Oslo who received a stem cell transplant in 2020 to treat myelodysplastic syndrome, a type of blood cancer. His donor, his own brother, unexpectedly carried the CCR5-delta32 mutation. Four years after discontinuing antiretroviral drugs, no traces of HIV have been detected in his body. This case was published in the journal Nature Microbiology and follows earlier reports of sustained remission in other patients, including Adam Castillejo, the “London patient,” who has remained off treatment since 2019.
All ten cured individuals shared a common path: they required stem cell transplants for life-threatening cancers such as leukemia or lymphoma, not for HIV treatment. The transplants replaced their vulnerable immune cells with donor cells resistant to HIV due to the CCR5-delta32 mutation. This genetic variant, found naturally in about 1% of people of Northern European descent, blocks the CCR5 co-receptor that HIV uses to infect cells. Without this entry point, the virus cannot establish new infections, and any residual virus gradually declines.
While stem cell transplantation is too risky and costly to serve as a general HIV cure, these cases have provided critical proof of concept. They confirm that eliminating HIV from the body is achievable and have guided research toward safer, scalable strategies. Scientists are now exploring gene editing techniques, such as CRISPR, to replicate the CCR5-delta32 mutation in a patient’s own stem cells. Others are investigating broadly neutralizing antibodies and therapeutic vaccines designed to induce long-term immune control without daily medication.
The progress has not gone unnoticed in the scientific community. At the Conference on Retroviruses and Opportunistic Infections (CROI) in February 2026, held in Denver, researchers presented data from the RIO trial showing that more than half of participants who received broadly neutralizing antibodies maintained low or undetectable viral loads for over 20 weeks after stopping antiretrovirals, with two individuals remaining off treatment for more than a year. These findings suggest that immune-based therapies could lead to sustained remission, even if complete eradication remains elusive for most.
Despite these advances, experts caution against overstatement. Sharon Lewin, president-elect of the International AIDS Society and director of the Doherty Institute in Melbourne, emphasized that the stem cell transplant approach is only justified for patients with both HIV and a malignancy requiring such intervention. “We are not close to a widely applicable cure,” she stated in a 2024 interview, “but each case teaches us something new about where the virus hides and how to target it.”
Globally, nearly 40 million people live with HIV, according to UNAIDS. While antiretroviral therapy has transformed HIV into a manageable chronic condition, lifelong treatment is required, and access remains uneven, particularly in low- and middle-income countries. A safe, affordable cure would represent a monumental public health breakthrough, reducing stigma, treatment burden, and long-term healthcare costs.
Research into HIV cure strategies continues through international collaborations such as the Martin Delaney Collaboratories, funded by the U.S. National Institutes of Health. These teams are investigating various approaches, including “shock and kill” methods to activate latent virus and immune therapies to eliminate it. As of early 2026, no alternative to stem cell transplantation has yet achieved confirmed cure in multiple individuals, but several candidates are in early-phase clinical trials.
The next major milestone in HIV cure research will be presented at the International AIDS Society Conference on HIV Science, scheduled for July 2026 in Brisbane, Australia. Researchers expect to share updates on gene therapy trials, antibody-based interventions, and long-acting formulations aimed at achieving sustained remission. Until then, the ten confirmed cases stand as enduring evidence that HIV, while not yet curable at scale, can be defeated.
For readers seeking reliable, up-to-date information on HIV treatment and cure research, trusted sources include the World Health Organization’s HIV department, the U.S. National Institute of Allergy and Infectious Diseases, and peer-reviewed journals such as The Lancet HIV and Nature Medicine. These organizations regularly publish guidelines, trial results, and expert commentary on advances in the field.
We invite you to share your thoughts on this development in the comments below and to spread awareness by sharing this article with others who may find it informative.